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Abstract: Myelin disorders burden millions of people around the world, yet existing therapies are inadequate to cure them. Current
remedies commonly treat the symptoms with minimal to no effect on the actual cause of the disorder. The basis and/or the mechanism
of demyelination is not known for many of the disorders either. In recent years, stem cells of variable origin have been used in clinical
trials as transplant agents to restore the defective biochemical process or the damaged tissue. We summarize the outcomes of these
trials for demyelination disorders. The capability of reprograming mature cells into stem cells equips researchers with a new tool to
replicate disease phenotypes in cell culture dishes for basic research and therapeutic screens. The applications of in vitro myelination
disorder models are also discussed. The combined outcome of the discussed studies offers a promising future as stem cell transplantation
generally results in decreased symptoms and improved quality of life. However, the mechanism of action of the interventions is not
known and in cases of negative outcomes the reasons are usually obscure. Further basic science studies along with clinical interventions
should close the knowledge gap and should help spread the positive results to a larger population.
Key words: Stem cells, induced pluripotent stem cells, myelin, Pelizaeus–Merzbacher disease, adrenoleukodystrophy, multiple sclerosis,
subacute sclerosing panencephalitis

1. Introduction
Myelin is a lipid-rich insulating substance made of multiple
layers of compacted cell membranes. Oligodendrocytes of
the central nervous system (CNS) ensheath the axons to
form myelin that insulates segments of an axon for faster
action potential conduction and to provide trophic support
(Griffiths et al., 1998; Nave, 2010; Simons and Nave, 2015).
Oligodendrocytes are required for the proper functioning
and survival of the neuron. Improper development of
myelin or damage to the existing myelin leads to interrupted
signal propagation over the axon and disrupted metabolic
support, resulting in failure of neuronal function followed
by atrophy of the neuron (Siegel, 2006; Peru et al., 2008;
Nave, 2010; Miron et al., 2011). Thus, strategies to activate
and protect the oligodendrocyte progenitor cells (OPCs)
residing in the CNS to replace the damaged myelin and
to supply exogenous myelination-capable cells when
endogenous OPCs are inadequate to remyelinate have
been in the spotlight to treat demyelination diseases (Peru
et al., 2008; Miron et al., 2011; Potter et al., 2011; Gupta
et al., 2012). In this review, such therapeutic approaches
taken against Pelizaeus–Merzbacher disease (PMD),
adrenoleukodystrophy (ALD), multiple sclerosis (MS), and
subacute sclerosing panencephalitis (SSPE) are discussed.
* Correspondence: bekerman@medipol.edu.tr
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Human clinical trials for all four diseases are summarized.
Additionally, stem cell transplantation therapy for spinal
cord injury is investigated as demyelination of axons is one
of the main symptoms of the injury.
In recent years, a new tool has emerged to investigate
neurodegenerative diseases in vitro. iPSCs carry the
genotype of the person they are derived from. Hence, iPSCs
derived from patients have the ability to reflect the cellular
pathophysiology of the disease and are increasingly being
used to study neurodegenerative diseases (Marchetto et
al., 2008, 2010; Havlicek et al., 2014; Marchetto and Gage,
2014). Advances have been made to use mouse ESCs
derived from oligodendrocytes and neurons as a model
of myelin formation in vitro and test drug candidates
to treat demyelination diseases (Deshmukh et al., 2013;
Kerman et al., 2015). The techniques can be adapted to
use human iPSCs. Patient iPSCs can be differentiated
into oligodendrocytes and neurons to monitor defects in
myelin formation (Figure). Additionally, these models are
ideal platforms to test candidate drugs on human cells
before clinical trials. This review discusses such potential
uses of iPSCs as in vitro models of myelination and myelin
disorders.
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2. Pelizaeus–Merzbacher disease
PMD is an X-linked recessive disorder involving mainly the
CNS with minor effects in the peripheral nervous system
(Hobson and Garbern, 2012; Han et al., 2013). Mutations
in the proteolipid protein 1 gene (PLP1) are responsible
for PMD. One in 200,000 to 500,000 live births has PMD
(Gupta et al., 2012; Torii et al., 2014). Individuals suffering
from PMD have deficiencies of intellectual functions and
motor skills involving walking, muscle stiffness, problems
with movement and balance (ataxia), and involuntary
jerking, with an average life span of approximately 30 years
(Hobson and Garbern, 2012; Han et al., 2013).
Studies using transgenic mice and cells transfected with
the PLP1 gene suggest that accumulation of the excess or
misfolded PLP protein in the secretory pathway revealed
the cellular basis of the disorder (Readhead et al., 1994;
Gow and Lazzarini, 1996; Karim et al., 2010; Saher et al.,
2012). The PLP is not delivered to the myelin membrane in
sufficient amounts. Additionally, accumulated PLP triggers
the unfolded protein response and attenuates delivery of
cholesterol and maybe other cargo to the cell membrane.
The oligodendrocyte metabolism is disrupted, resulting
in abnormal differentiation, failure to form typical myelin
structure, and apoptosis. A human iPSC-based model of
PMD also supports this mechanism (Numasawa-Kuroiwa
et al., 2014). iPSCs derived from two PMD patients were
differentiated into oligodendrocytes and neurons. Cellular
phenotypes of oligodendrocytes were investigated in
detail and defects in myelin morphology were recorded
for human cells, allowing the study of correlations among
oligodendrocyte biology, genetic mutations that people
carry, and the pathophysiology of PMD (Figure).
Currently available treatments for PMD are rather
restricted and focus on alleviating the symptoms rather
than curing the myelin deficit (Uchida et al., 2012; Torii
et al., 2014). Thus, transplantation of cells capable of
myelination has become a target as a treatment for PMD.
Oligodendrocyte and Schwann cell transplantation to
donor animals has been experimentally investigated since
the 1980s (Table 1) (Duncan et al., 1981, 1988). Recently,
animal models are being used to test the feasibility of
transplantation of human cells (Table 1). For example, NSCs
isolated from donated fetal brains (Uchida et al., 2012) and
human glial progenitor cells (GPCs), either isolated from
donated fetal brains or from surgical samples (Windrem et
al., 2008), are transplanted into the dysmyelinated shiverer
mouse model. These cells spread around the CNS and
myelinated axons restore impulse transduction across the
axons. Since fetal tissue as a transplantation material in the
clinic may have several limitations, including availability
as a constant source, moral objection of the recipient,
and immune system complications due to the allogenic
nature of the cells, iPSC-derived cells are being tested as an

alternative. Human iPSC-derived OPCs have been shown
to efficiently myelinate axons of shiverer mice (Wang et al.,
2013). Importantly, neither of the transplanted progenitor
cells showed any tumorigenic activity.
Human fetal NSCs that were not tumorigenic in mouse
(Uchida et al., 2012) were tested for safety and efficacy in
an open-label phase I clinical trial (Table 2) (Gupta et
al., 2012). The 4 male patients involved in the trial had
early-onset severe PMD due to amino acid substitution
mutations in PLP1 and were between 14 months and 66
months of age. The NSCs were transplanted surgically
into the frontal lobe white matter. Patients received
immunosuppressants for 9 months after transplantation
due to the allogenic nature of the NSCs. No severe adverse
effects related to the transplantation procedure or to
immunosuppression were observed. Twelve months after
transplantation, the mental and physical functions of all
four patients were stable or improved, such as the ability
to self-feed. Neurological improvements such as reduced
nightly continuous positive airway pressure requirements
were observed. Consistently, MRI data indicated increased
myelination in the regions of transplantation. A longterm follow-up of these four patients is currently ongoing
(https://clinicaltrials.gov/ NCT01391637).
Umbilical cord blood (UCB) is a source of
hematopoietic stem cells (HSCs) and has been successfully
transplanted for treatment of many inherited metabolic
diseases (Prasad et al., 2008). UCB transplantation can
stabilize the disease progression if performed early. With
this premise, Wishnew et al. (2014) transplanted UCB in
two young boys with PMD (Table 2). One patient had a
duplication of and the other had an aberrant splicing
mutation in the PLP1 gene. At the ages of 9 months and
29 months, the patients underwent UCB transplantation
after myeloablative chemotherapy as the cords came
from an unrelated donor. Both patients showed improved
disease phenotype and no severe complications related
to the transplantation procedure after 7-year and 1-year
follow-ups. Modestly improved motor skills and cognitive
skills were reported. These may be associated with increase
in myelination observed by MRI. However, due to lack
of MRI data on the natural course of the disease, such a
statement is not conclusive.
The outcomes of stem cell transplantation therapies
for PMD are very encouraging as all patients show stable
or improved motor skills and mental abilities. Increased
myelination within the CNS suggests that these interventions
are, at least in part, acting through an expected mechanism.
All patients tolerated the allogenic cells even after removal
of immunosuppression. It is especially noteworthy that one
of the boys who received UCB transplantation has shown
positive results for 7 years and can attend mainstream
schooling with some extra support.
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Figure. Modeling demyelination disease using iPSCs. Patient and control cells are reprogrammed to the pluripotent state to generate
iPSCs, which in turn are differentiated into oligodendrocytes and neurons. In a controlled in vitro environment oligodendrocytes
form myelin. The oligodendrocytes, neurons, and myelin can be analyzed in detail for metabolic changes, cellular morphology,
maturation, and myelination potential. The evaluated disease phenotype feeds into the analysis process where informed choices can
be made to select candidate drugs and therapies. These selected few candidates or a large number of compounds can be screened
using the cells to examine their effects on the disease pathophysiology. Successful therapeutic strategies and compounds could be
identified and employed to improve the lives of patients.

3. Adrenoleukodystrophy
ALD is caused by disruption of the ATP-binding cassette
subfamily D member 1 gene (ABCD1) that is on the X
chromosome (Kemp et al., 2001; Baarine et al., 2015). At
least 517 different mutations disrupting the ABCD1 gene
have been identified with a conservative incidence rate of 1
in 20,000, which may be as high as 1 in 14,000 (Kemp et al.,
2001, 2010). The encoded protein (also known as ALDP)
localizes to the peroxisomal membrane and is involved
in transfer of very-long-chain fatty acids (VLCFAs) into
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peroxisomes, where VLCFAs are oxidized. Although
ALD is characterized by accumulation of VLCFAs, the
mechanism of myelin disruption is unknown. People with
ABCD1 mutations can show a variety of phenotypes, the
most devastating being childhood-onset cerebral ALD
(ccALD). From 30% to 35% of ALD patients start showing
demyelination within the cerebrum between the ages of
3 to 10 years (Kemp et al., 2001; Miller et al., 2011). The
neurological and cognitive decline is very quick; usually
total disability is evident within 3 years of diagnosis.
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Table 1. A synopsis of the stem cell transplantation tests in animal models. This table is aimed at providing a small sample of studies
involving transplantation of various stem cells into animal models with defective myelin in order to supplement human clinical trials.
Model

Study

Quaking mouse
(CNS hypomyelination)

- Lysolecithin induced demyelination
Cells: Rat Schwann cells
- Immunosuppression administered
Transplantation: Injection into the spinal cord
- Myelination of spinal neurons by Schwann
Parkin and PACRG genes mutated
cells
(Duncan et al., 1981)
- Minimal to no migration of Schwan cells

Myelin-deficient rat
(proteolipid protein gene mutated)

Cells: Rat CNS cells (mixture) and Schwann - Cells migrated away from injection site
- Transplanted oligodendrocytes myelinated
cells
axons of the spinal cord
Transplantation: Injection into the spinal cord
- Transplanted Schwann cells also myelinated
CNS axons
(Duncan et al., 1988)

Cells: Fetal human glial progenitor cells
Transplantation: Injection into brain at several
locations
Mice are also immunodeficient (rag2-/-)
(Windrem et al., 2008)

Shiverer mouse
(MBP gene mutated)

Outcomes

-

Human cells myelinated in the mouse brain
Restored conduction velocity and nodes
Increased neurological function
Increased survival and decreased seizures
Cells were nontumorigenic

- hNSCs turned into oligodendrocytes
Cells: Human neural stem cells (hNSCs)
preferentially
Transplantation: Injection into brain at several
- Robust myelination
locations
- Restored conduction velocity and nodes
Mice are also immunodeficient (rag2-/-)
- Myelin detected by magnetic resonance
(Uchida et al., 2012)
imaging

Cells: Human iPSC-derived oligodendrocyte
progenitor cells (hiPSC-OPCs)

- hiPSC-OPCs turned into oligodendrocytes
and astrocytes

Transplantation: Injection into brain
Mice are also immunodeficient (rag2-/-)
(Wang et al., 2013)

-

Robust myelination of the entire brain
Restored nodes of Ranvier
Increased survival
Cells were nontumorigenic
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Table 1. (Continued).
Cells: Mesenchymal stem cells (MSCs) from
the same strain of mice
Transplantation: Intravenous injection
mmunized by myelin oligodendrocyte
glycoprotein
(Zappia et al., 2005)

Cells: Human bone marrow stromal cells
(hBMSCs)
Transplantation: Intravenous injection
Immunized by proteolipid protein
(Zhang et al., 2005)

Experimental autoimmune
encephalomyelitis (EAE)

Increased neurological function
Reduced demyelination of CNS
Reduced immune cell infiltration to CNS
hBMSCs infiltrate brain
Increased proliferation of oligodendrocyte
lineage cells
- Elevated BDNF levels in the brain
-

Serum IFN-β levels were elevated
Reduced demyelination of CNS
Reduced immune cell infiltration to CNS
Reduced levels of activating cytokines
Elevated BDNF and NGF levels in the brain
MSCs-IFN-β migrate into CNS
Reduced blood–brain barrier permeability

Cells: Human mesenchymal stem cells
(MSCs) engineered to secrete interferon-beta
(IFN-β)
Transplantation: Intravenous injection
Immunized by myelin oligodendrocyte
glycoprotein
(Ryu et al., 2013)

-

Cells: Wild-type (wt) or Fas-deficient (lpr)
mouse neural stem cells (NSCs)
Transplantation: Injection into brain
Immunized by myelin oligodendrocyte
glycoprotein
(Hackett et al., 2014)

- lpr-NSCs exhibit increased survival and
differentiation
- Increased neurological function
- Reduced immune cell infiltration to CNS
- NSCs migrated in the CNS
- NSCs remained as progenitors around the
CNS lesions
- Both wt- and lpr-NSCs showed same effects
- Transplanted NSCs may have more of an
immunomodulatory role

Another common type of ALD is adrenomyeloneuropathy
(AMN), which involves axonopathy of mostly spinal cord.
AMN onset is at 28 ± 9 years of age and it progresses more
slowly.
Correlation between ALD severity and either ABCD1
mutations or plasma VLCFA levels has not been observed
(Kemp et al., 2010; Jang et al., 2011). Reflecting such
complexity, mice with mutated ABCD1 gene fail to
replicate ALD phenotypes, especially that of ccALD.
Therefore, iPSCs derived from patients offer an ideal
platform to study the disease pathophysiology and test
drug candidates. Indeed, VLCFA accumulation is observed
in oligodendrocytes derived from ccALD and AMN iPSCs
(Jang et al., 2011; Baarine et al., 2015). Consistent with the
disease severity, ccALD oligodendrocytes accumulated
more VLCFAs than AMN oligodendrocytes. The excess
VLCFA was not observed in the undifferentiated iPSCs
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Reduced demyelination of CNS
Reduced immune cell infiltration to CNS
Not beneficial after disease stabilization
MSCs migrated primarily to lymph nodes
and spleen
- T-cell activation was suppressed
-

(Jang et al., 2011), but it was observed for a subset of the
lines when differentiated into neurons (Jang et al., 2011;
Baarine et al., 2015). Additionally, ccALD iPSC-derived
astrocytes were more prone to inflammatory activity
(Baarine et al., 2015). Jang et al. (2011) also tested effects
of lovastatin and 4-phenylbutyrate, two compounds
known to lower VLCFA levels in fibroblasts, on ccALD
iPSC-derived oligodendrocytes. Intriguingly, both drugs
lowered the VLCFA level, though only lovastatin’s effect
was statistically significant. These results demonstrate the
utility of iPSCs for studying complex disease phenotypes
and testing candidate drugs for ALD and, more generally,
other demyelinating diseases in vitro (Figure).
ALD patients have been transplanted with HSCs
in the form of bone marrow or UCB from either
immunologically matched or mismatched sources since
1982 (Table 2) (Peters et al., 2004). A comparison of
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Table 2. Clinical trials of stem cell transplantation to treat myelin disorders. The transplantation materials used in and the outcomes of
the human clinical trials discussed in this review are summarized.
Myelin disorder

Study

Outcomes

Cells: Fetal nervous system stem cells
Transplantation: Injection into the brain white matter
n = 4 patients
(Gupta et al., 2012)

-

No severe complications
Stable or improved mental function
Improved neurological function
Increased myelination

Cells: Allogenic umbilical cord blood
Transplantation: Intravenous infusion
n = 2 patients
(Wishnew et al., 2014)

-

No severe complications
Improved disease phenotype
Improved motor skills and cognitive skills
Increased myelination

Cells: Autologous mesenchymal stem cells (MSCs)
Transplantation: Intrathecal injection
n = 10 patients
(Mohyeddin Bonab et al., 2007)

-

No severe complications
Variable disability scores
Mostly stable plaques
Minimally improved neurological function

Cells: Autologous mesenchymal stem cells
Transplantation: Intrathecal only or intrathecal and
intravenous injection
n = 10 patients and 5 patients
(Karussis et al., 2010)

-

No severe complications for 25 months
Mostly decreased disability scores
Increased neurological function
No new demyelinating plaques
Suppressed activated lymphocytes
MSCs disseminated from injection site

Cells: Autologous mesenchymal stem cells
Transplantation: Intravenous injection
n = 10 patients; 8 controls
(Connick et al., 2011)

- No severe complications
- Improved clinical trial strategy to evaluate MS
therapies

PMD

MS

Cells: Lymphocyte-depleted autologous hematopoietic
stem cells (HSCs)
Transplantation: Intravenous infusion with high-dose
immunosuppressive therapy
n = 26 patients
(Bowen et al., 2012)

- 1 death due to infection
- 2 severe adverse effects with worsening disability
scores
- Mild complications
- Stable or worsened disability scores
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Table 2. (Continued).
Cells: Allogenic umbilical cord blood or hematopoietic
stem cells
Transplantation: Intravenous injection with slight
variations among centers
n = 94 patients from 43 centers
(Peters et al., 2004)

-

Method: Retrospective analysis comparing data of
Peters et al. (2004) with data from nontransplanted
patients
n = 94 transplanted 283 nontransplanted patients
(Mahmood et al., 2007)

- Increased survival rate of ccALD patients (especially
early-stage patients)
- Not recommended for patients at advanced stages or
without cerebral involvement

Cells: Allogenic hematopoietic stem cells
Transplantation: Intravenous injection
n = 60 patients
(Miller et al., 2011)

- No severe complications
- Increased survival of patients who received early in
disease
- Benefit to neurological function

Low rate of severe complications
86% engraftment of donor cells
Increased survival of early stage patients
Not recommended for late stage patients

ALD

- Functional ABCD1 was introduced into HSCs using
Cells: ABCD1 gene corrected autologous hematopoietic
lentivirus
stem cells
- Longitudinally, 10%–15% of transplanted HSCs
Transplantation: Intravenous infusion after complete
expressed ABCD1 (ALD) protein
myeloablation
- Decreased demyelination
n = 2 patients
- Neurological benefits similar to HSC transplantation
(Cartier et al., 2009)
- Decreased plasma VLCFA levels

SSPE

Cells: Autologous mesenchymal stem cells
Transplantation: Intrathecal and intravenous injection
n = 5 patients
(Kuskonmaz et al., 2015)

transplanted versus nontransplanted ccALD patients (n =
94 and n = 283, respectively) showed that hematopoietic
cell transplantation (HCT) is very effective when
performed at the early stages of the disease with increased
survival; however, at later stages of disease, the benefit of
HCT was minimal due to complications arising from the
HCT procedure (Mahmood et al., 2007). A more recent
study involving 60 ccALD patients who underwent HCT
in a single institution reiterated similar findings (Miller
et al., 2011). Patients receiving HCT with lower cerebral
disease component benefit more in terms of survival and
neurological function (Table 2). For patients that are not
eligible for allogenic HCT, correction of the ABCD1 gene
within their own HSCs is also being explored (Cartier et
al., 2009). Transplantation of these genetically engineered
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-

1 death before the evaluation
1 death from disease progression
1 deteriorated to stage III
2 remained stable

HSCs offers similar benefits to HCT (Table 2). Thus, ALD
patients without a matched donor or older patients who
show severe adverse reaction to allogenic HSCs may soon
benefit from HCT.
All of these studies underline the importance of
early diagnosis of ccALD. Neonatal mutation screening
will significantly improve outcomes of transplantation.
Despite years of clinical application, the mechanism of
the positive effect of transplanted cells is not known.
More studies comparing pathophysiology before and after
transplantation are required.
4. Multiple sclerosis
MS is a demyelinating disorder with a significant
inflammatory component (Compston and Coles, 2008;
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Constantinescu et al., 2011). Myelin loss disrupts the
ability of the nervous system to efficiently communicate,
resulting in physical, mental, and psychiatric problems
(Compston and Coles, 2008). The immune cells invade
the CNS to remove myelin debris and are involved in
the death of neurons and oligodendrocytes. There is no
cure for this disease that affects over 2.3 million people
worldwide (www.nationalmssociety.org). Most, if not all,
of the current therapies for MS target the immune system
(Compston and Coles, 2008). Although immunotherapies
slow down or inhibit further demyelination and lessen the
progression of the disease, they usually are not sufficient to
enhance remyelination.
Experimental autoimmune encephalomyelitis (EAE)
is an animal model used to investigate inflammatory
demyelinating diseases of the CNS including MS
(Constantinescu et al., 2011) (see also Duncan et al. (2011)
for a review of animal models of leukodystrophies). The
animal models, mostly those of rodents but also nonhuman
primates, are immunized with CNS tissue homogenate or
peptides of specific myelin proteins to induce the immune
system of the animal and initiate EAE. Activated T cells
targeting myelin enter the brain and spinal cord and induce
inflammation leading to demyelination and cell death. EAE
is being used to study many aspects of MS, including the
T cell-mediated autoimmune component of MS (Carbajal
et al., 2015). Many of the current therapies for MS have
been investigated with EAE models, including stem cell
transplantation approaches (Table 1) (Constantinescu et
al., 2011).
Despite its many benefits, EAE fails to reflect the
complexity and heterogeneity of MS (Hartley et al., 2014).
Patient-derived iPSCs may close the gap between animal
models and MS pathophysiology. A total of five iPSC
lines from MS patients have been published; however, no
clear phenotype specific to MS has been recognized so far
(Song et al., 2012; Douvaras et al., 2014). This may be due
to several reasons: 1) MS is a complex disease with both
genetic and environmental components; 2) in these studies
oligodendrocytes but not the myelin was investigated; and
3) the immune component was missing in the in vitro
models. Future studies comparing MS patient-derived
myelin to controls in a controlled in vitro environment are
required for better understanding of the disease.
Mesenchymal stem cells (MSCs) offer an easily
accessible form of stem cells as they are present in many
adult human tissues (Pountos and Giannoudis, 2005).
They can differentiate into many cell types including
bone, cartilage, fat, muscle, and tendon. It is hypothesized
that MSCs can suppress the immune system, which can
damage neurons and oligodendrocytes as discussed above
(Darlington et al., 2011; Cohen, 2013). MSCs can also
stimulate the neuronal repair mechanisms by secreting

neuroprotective factors. These tissue protective and
immunomodulatory characteristics of MSCs make them
intriguing candidates for MS therapy. For instance, in one
study, MSCs migrated to demyelinating regions of the
inflamed CNS and inhibited the myelin-specific T cells in
an EAE model and regulated the cytokines released from
T helper 1 (Th1) and T helper 17 (Th17) (Bai et al., 2009).
Engineered MSCs exhibit superior ability over naïve
MSCs to treat MS. Interleukin-10 transfected into MSCs
showed significant inhibitory activity on the proliferation
of CD4+ T lymphocytes of EAE mice and significantly
improved remyelination (Liao et al., 2016). Additionally,
interferon-β-secreting MSCs reduced further injury to
the blood–brain barrier permeability and also increased
remyelination (Ryu et al., 2013).
As discussed above, NSC or OPC transplantation
enhances myelination of axons in dysmyelinated
mouse models (Uchida et al., 2012; Wang et al., 2013).
Remarkably, NSCs have immunomodulatory effects as
well. Chemokines secreted by NSCs impair recruitment of
immune cells to the CNS (Ravanidis et al., 2015). Leukemia
inhibitory factor produced by NSCs inhibits pathogenic
Th17 cell differentiation resulting in amelioration of EAE
(Cao et al., 2011). Transplantation of Fas-deficient NSCs
decreases the inflammatory infiltration into the CNS
by inducing apoptosis of Th1 and Th17 cells (Hackett et
al., 2014). NSCs may exert their immunomodulatory
effect without entering the CNS (Ben-Hur, 2008). When
injected intravenously to an EAE mouse, NSCs traveled
to the lymph nodes and spleen rather than migrating
into the CNS. There, they attenuated T-cell activation
and reduced inflammatory response to myelin. Similarly,
transplantation of NG2+ progenitor cells, which can
mature into oligodendrocytes but may also have other
resident functions in the CNS, into EAE mice reduced
immune cell infiltration and increased myelination (Bai et
al., 2013).
To investigate the feasibility of MSC transplantation in
humans, 10 MS patients received bone marrow-derived
autologous MSCs intrathecally (Mohyeddin Bonab et al.,
2007). Patients’ neurological functions improved slightly
(Table 2). The Expanded Disability Status Scale (EDSS) is
a tool for quantifying disability of MS. Posttransplantation
EDSS scores of patients were too variable to be conclusive
with both increased and decreased scores. Similarly,
changes in demyelinating plaque numbers varied from
patient to patient but were generally stable. In a phase I/
II human clinical trial, the immunological effects of bone
marrow-derived autologous MSCs were examined in 15
patients (Karussis et al., 2010). No major adverse reactions
to the transplantation procedure were evident within
the duration of study (25 months; Table 2). Neurological
function either improved or was stable as measured by the
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EDSS. No new plaques developed. Activated lymphocytes
and antigen-presenting cells were suppressed after
transplantation; however, the activated T-cell population
(CD4- and CD25-double positive) increased. Intriguingly,
MSCs, as traced by MRI, disseminated from the injection
site within the CNS. A more recent study addressed the
trial design features to better measure the benefits and
risks of stem cell transplantation in MS patients (Connick
et al., 2011). Ten patients and 8 controls were assessed
both before and after transplantation to minimize the
effect of variance observed between patients and for one
patient throughout the disease course (Table 2). The safety
of autologous MSC transplantation was reiterated. The
authors suggested that assessing neuroprotection with
specific methods rather than measuring wider neuronal
functions is a more relevant evaluation of the intervention.
With the premise of generating a myelin-nonreactive
immune system, patients’ immune systems were almost
completely ablated by high-dose immunosuppressive
therapy followed by autologous HCT in 26 advanced
MS patients (Bowen et al., 2012). Complications due to
the transplantation procedure were more severe than
in previous interventions (Table 2). Improvement of
neurological functions of the patients was not significant.
The benefits of transplantations in MS patients are
minimal at best with worsening disability being common.
The positive outcomes may be concealed due to the small
group sizes and variable course of MS. iPSC models are
also not able to replicate disease phenotype. More patient
cell lines should be investigated.
5. Subacute sclerosing panencephalitis
SSPE is a rare, progressive neurological disorder of the
CNS caused by persistent measles virus (MV) infection
(Schonberger et al., 2013). It more commonly affects
children and young adults in less developed countries. The
SSPE incidence rate in the United States is reported to be
6.5–11 cases per 100,000 acute measles infections (Bellini
et al., 2005), while the estimated number of SSPE patients
in Turkey is approximately 3000 (www.sspedernegi.org/).
It is predicted that MV accesses the CNS during primary
infection by a hematogenous route, where it stays latent
for on average 4 to 10 years (Schneider-Schaulies et al.,
2003; Campbell et al., 2007; Anlar and Yalaz, 2011). In the
first stage of the disease, behavioral changes and mental
deterioration are observed (Schonberger et al., 2013). As
SSPE progresses motor function declines; spasms, muscle
contractions, and rigidity may be observed. Neurological
function also deteriorates, resulting in dementia, seizures,
and unresponsiveness. The final stage starts with entry into
coma, which progresses to a persistent vegetative state. Loss
of the brain’s control over the autonomic nervous system,
heart failure, or fever causes the death of the patient. SSPE
symptoms are consistent with neurological deterioration
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due to demyelination and neuronal death (SchneiderSchaulies et al., 2003; Anlar and Yalaz, 2011). The survival
period after onset of symptoms is typically between 1 and
3 years (Garg, 2008; Gutierrez et al., 2010).
The distinct processes leading to infection of cells in the
brain are poorly understood and no cure for SSPE exists
(Schneider-Schaulies et al., 2003; Anlar and Yalaz, 2011).
As MSCs have been used in ALD with positive outcomes
and in MS for their immunomodulatory characteristics,
Kuskonmaz et al. (2015) transplanted five SSPE patients
with autologous bone marrow-derived MSCs. One
patient died of respiratory problems prior to evaluation
and none of the remaining four patients showed any
improvements (Table 2). Two patients remained stable;
one patient deteriorated and one patient died due to
disease progression. New inﬂammatory lesions developed
in two of the patients. The variability of SSPE course and
the small number of patients enrolled in the trial may
mask any potentially gained benefits. Encouragingly,
none of the patients developed any adverse effects to the
transplantation procedure.
Currently, stem cell therapies for SSPE are in their
infancy. New animal models have to be established for
safety and efficacy testing of cells before human trials.
Pretransplantation screenings of autologous stem cells
for latent MV infection may have positive outcomes.
Allogenic cells isolated from immunologically matched
sources may also benefit patients, as was observed for
other myelination disorders.
6. Spinal cord ingury
Spinal cord injury (SCI) affects millions of people
worldwide and constitutes a substantial health care burden
(Salewski et al., 2015). The most common type of SCI, spinal
contusion, causes permanent motor and sensory function
loss due to major tissue death and cell damage to the injury
site and its close proximity. The primary physical trauma
to the spinal cord leads to vascular rupture, hemorrhage,
and cell death. Oligodendrocytes and neurons are lost by
necrosis. This initial injury is followed by the secondary
injury, in which the lesion area grows gradually and chronic
inflammation is present (Allison and Ditor, 2015). During
this phase blood flow is reduced, resulting in ischemia,
and free radical production increases, the blood–brain
barrier breaks down, and immune cells infiltrate the injury
site and the surrounding area. The secondary insults also
contribute to necrosis of neurons and oligodendrocytes
and demyelination (Almad et al., 2011).
Stem cells arise as a potential therapy to replace the lost
cells, especially the oligodendrocytes to repair the myelin
(Cummings et al., 2005; Barnabe-Heider and Frisen, 2008;
Sharp et al., 2010; Li and Leung, 2015). Embryonic stem
cells (ESCs) and induced pluripotent stem cells (iPSCs),
however, cannot be directly transplanted because these
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cells can proliferate rapidly and turn tumorigenic. Rather,
they are first converted into various cell types of the
nervous system such as neural stem cells (NSCs), OPCs,
and motor neurons and then transplanted. In animal SCI
models, transplanted mouse or human NSCs and OPCs
contribute to remyelination, axon regeneration, and
functional recovery (Cummings et al., 2005; BarnabeHeider and Frisen, 2008; Sharp et al., 2010; Li and Leung,
2015). Human NSCs transplanted into the injured
spinal cord of mouse are more likely to become mature
oligodendrocytes than NSCs transplanted into uninjured
spinal cord (Sontag et al., 2014). This may be a feature of
the injury highlighting a need to remyelinate axons in the
injury site.
The first clinical trial of stem cell therapy for SCI was
run in 2009 by the Geron Corporation to test the safety
of human ESC-derived OPCs (ir.geron.com; https://
clinicaltrials.gov/ NCT01217008). The OPCs are derived
from human ESC line WA01 (H1) using a protocol originally
established by the Keirstead Lab (Sharp et al., 2010).
Approximately 2 million cells were administered within 14
days of injury to 5 patients with complete thoracic SCI. The
patients received immunosuppressants for 2 months. No
adverse events were reported in the trial or by the followup studies ever since (ir.geron.com; www.biotimeinc.com)
(Lebkowski, 2011). Additionally, the transplanted OPCs
might have played a role in the reduction of the injury site
in 4 of the patients (www.biotimeinc.com). Encouraged
by these results, Asterias Biotherapeutics is undertaking a
phase I/IIa human clinical trial (https://clinicaltrials.gov/
NCT02302157). OPCs derived by the same protocol will
be transplanted to patients with cervical SCI in increased
doses primarily to evaluate the safety of the treatment,
but also the neurological function of the patients will be
monitored (Priest et al., 2015).
In an ongoing phase I/IIa human clinical trial, Shin
et al. (2015) transplanted human NSCs that were derived
from human fetal telencephalon to 19 patients with
cervical SCI. After approximately 2 months of injury, 2.0 ×
108 cells were injected into the lesion area. Patients received
an immunosuppressant for 9 weeks. Motor functions of 5
of the patients were improved 1 year after transplantation.
None of the patients showed neurological deterioration,
spasticity or tumor formation, or spinal cord damage due
to transplantation procedure (Shin et al., 2015).
The limited number of human clinical trials
demonstrates that SCI patients tolerate transplantation of
allogenic cells either derived from human ESCs or from
fetal tissue. Early outcomes of the trials suggest modest
improvement of neurological function for the patients.
These results are promising but to achieve significant
clinical betterment of the patients the transplantation

procedure needs to be optimized. More, a longer-term
monitoring of the transplanted patients is required to
evaluate the safety of transplanted cells for any adverse
effects.
7. Concluding remarks
The studies discussed in this review demonstrate that
stem cell transplantation offers a hope for incurable
demyelination disorders (Table 2). Thus, there are several
active studies registered in the National Institutes of Health
clinical trials database. Out of the 14 studies targeting
MS, 9 are currently recruiting patients. Three out of 5 of
active ALD trials and 1 out of 3 active PMD trials also
are recruiting volunteers. MSCs and HSCs from different
sources are pretty much evenly split as transplantation
material among trials. However, many challenges lie ahead
of a readily available therapy. One of them is the type of stem
cell to be used. MSCs and HSCs are easily accessible cells
and have immunomodulatory effects, but they themselves
do not participate in new myelin formation. NSCs and their
derivatives with more restricted fates, OPCs and GPCs, can
myelinate neurons while also suppressing lymphocytes.
No tumorigenic activity associated with transplantation of
these cells has been observed so far. Secondly, the source
of cells is a key issue. Some patients may object to receiving
fetal tissue-derived cells on moral grounds. Regardless, the
requirement of immunosuppression for allogenic cells may
also increase the risk that patients face. It may be possible
to correct the genetic defect of patients’ own MSCs or
HSCs for autologous transplantation for single-gene
mutation diseases such as PMD and ALD. Additionally,
iPSCs offer possibilities for autologous transplantations as
they can be differentiated into specific cell types such as
NSCs and OPCs. The investigations so far show that after
sorting out undifferentiated cells within the population,
these cells do not cause tumors after transplantation. For
genetic diseases, iPSCs will also require gene correction
before transplantation.
Patient-derived iPSCs are being used to study myelin
biology in vitro (Figure). Thus far, cellular disease
phenotypes of PMD and ALD but not of MS have been
replicated using iPSCs. The difference may rise from the
fact that more than one cell type is involved in MS without
known mutations while both PMD and ALD iPSCs carry
known mutations in a single gene. These observations
underlie the importance of using myelination-in-a-dish
approaches to study myelin formation.
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